stockrow
Saturday 7 November 2026
Export JANX’s income statement to Excel — free account
Janux Therapeutics, Inc.
JANX Healthcare Biotechnology
Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- +12.8%
- Free cash flow
- −94.5%
Quarter to September 2026, against a year earlier
17.63
1.57
+9.78%
Follow JANX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 4 | 9 | 8 | 11 | 10 | 33 | +28.8% | 29 | 8 | 8 | (5.3%) | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | +100.0 pt | ||||||
| EBT | — | — | — | (4) | (7) | (33) | (63) | (58) | (69) | (114) | (100) | +74.6% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | (898.32) | (732.22) | (721.18) | (651.62) | (1,136.25) | (299.95) | (1,136.2) pt | ||||||
| Net income | — | 0 | — | (4) | (7) | (33) | (63) | (58) | (69) | (114) | (100) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.15 | 0.21 | 0.18 | 0.20 | 0.16 | 0.53 | n/m | |||||
| Earnings | — | — | — | (5.98) | (7.41) | (1.39) | (1.52) | (1.32) | (1.28) | (1.83) | (1.59) | (17.9%) | ||||||
| Cash flow | — | — | — | (5.72) | (4.77) | (0.72) | (1.03) | (1.15) | (0.82) | (1.33) | (0.85) | (21.6%) | ||||||
| Capex | — | — | — | 0.00 | 0.00 | (0.06) | (0.16) | (0.04) | (0.01) | (0.02) | (0.01) | n/m | ||||||
| Free cash flow | — | — | — | (5.72) | (4.77) | (0.78) | (1.19) | (1.19) | (0.82) | (1.34) | (0.86) | (21.4%) | ||||||
| Book value | — | — | — | (5.90) | 7.63 | 15.57 | 7.73 | 7.82 | 19.03 | 15.44 | 14.45 | n/m | ||||||
| Shares, m | — | — | — | 1 | 1 | 24 | 41 | 44 | 54 | 62 | 63 | +112.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | 127.65 | 67.51 | 60.01 | 271.80 | 44.23 | 33.41 | 114.2 | ||||||
| P/B | — | — | — | — | — | 1.27 | 1.81 | 1.41 | 2.81 | 0.89 | 1.22 | 1.6 | ||||||
| EV/Sales | — | — | — | — | — | 24.55 | 29.54 | 17.45 | 174.98 | (5.76) | 5.00 | 48.2 | ||||||
| EV/FCF | — | — | — | — | — | (4.84) | (5.15) | (2.69) | (41.94) | 1.34 | (3.08) | (10.7) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (4) | (4) | (17) | (43) | (51) | (44) | (82) | (54) | +66.7% | |||||
| Capex | — | — | — | — | — | (1) | (6) | (2) | 0 | (1) | (1) | (8.4%) | ||||||
| Free cash flow | — | — | — | (4) | (4) | (18) | (49) | (52) | (44) | (83) | (54) | +67.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | (4) | 13 | 364 | 316 | 336 | 1,016 | 951 | 905 | n/m | |||||
| Net debt | — | — | — | (1) | (8) | (375) | (327) | (344) | (1,025) | (967) | (946) | +237.2% | ||||||
| Shareholders’ equity | — | — | — | (4) | 7 | 366 | 321 | 344 | 1,023 | 957 | 912 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (1,179.38) | (80.30) | (16.50) | (16.96) | (15.66) | (9.57) | (11.02) | (9.94) | +1,168.4 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (14,209.31) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 35.46 | 60.08 | (18.58) | (18.36) | (17.53) | (10.09) | (11.48) | (10.58) | (46.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 16 | 33 | 60 | 64 | 81 | 109 | — | +46.8% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.11 | 0.14 | 0.13 | 0.13 | 0.09 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026
Janux Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SPTX Seaport Therapeutics, Inc | $1.1B | — (loss-making) | — | — | n/m | −43.81% (below 0%: shrinking) | — | 0.00% | Compare |
| JANX Janux Therapeutics, Inc. | $981.9M | — (loss-making) | — (loss-making) | 0.00% | n/m | −94.49% (below 0%: shrinking) | 100.00% | (336.51%) | |
| IMTX Immatics N.V. | $924.8M | — (loss-making) | — (loss-making) | +97.71% (above 0%: growing) | n/m | −44.41% (below 0%: shrinking) | 100.00% | (734.95%) | Compare |
| MLTX MoonLake Immunotherapeutics | $919.2M | — (loss-making) | — | — | n/m | −1.89% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ODTX Odyssey Therapeutics, Inc. | $907.3M | — (loss-making) | — | — | n/m | — | 100.00% | 0.00% | Compare |
| SVRA Savara Inc. | $899.9M | — (loss-making) | — (loss-making) | — | n/m | −14.05% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| JBIO Jade Biosciences, Inc. | $896.7M | — (loss-making) | — | — | n/m | −115.11% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CTY City Therapeutics, Inc | $882.9M | — | — | — | — | — | — | — | Compare |
| ORIC Oric Pharmaceuticals, Inc. | $880.0M | — (loss-making) | — | — | n/m | −3.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $903.6M | — | — | — | — | −28.93% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 28 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 13.51m | (17.75m) | 104.78 |
| 2024 | 8.97m | 55.19m | 406.53 |
| 2023 | 4.19m | 1.05m | 81.47 |
Ownership
Directors and executive officers, together
7.90%
Entities affiliated with RA Capital Healthcare Fund, L.P.
19.99%
Entities affiliated with Janus Henderson Group plc
8.80%
State Street Corporation
6.30%
FMR LLC
5.80%
Blackrock, Inc.
5.50%
Entities affiliated with Prosight
5.20%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement